Omnicell Inc. Stock Upgraded (OMCL)

NEW YORK ( TheStreet) -- Omnicell (Nasdaq: OMCL) has been upgraded by TheStreet Ratings from hold to buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, expanding profit margins, solid stock price performance and notable return on equity. We feel these strengths outweigh the fact that the company has had sub par growth in net income.

Highlights from the ratings report include:
  • OMNICELL INC's earnings per share declined by 33.3% in the most recent quarter compared to the same quarter a year ago. This company has reported somewhat volatile earnings recently. But, we feel it is poised for EPS growth in the coming year. During the past fiscal year, OMNICELL INC increased its bottom line by earning $0.15 versus $0.02 in the prior year. This year, the market expects an improvement in earnings ($0.55 versus $0.15).
  • Compared to its closing price of one year ago, OMCL's share price has jumped by 39.59%, exceeding the performance of the broader market during that same time frame. We feel that the stock's sharp appreciation over the last year has driven it to a price level which is now somewhat expensive compared to the rest of its industry. The other strengths this company shows, however, justify the higher price levels.
  • The gross profit margin for OMNICELL INC is rather high; currently it is at 58.60%. It has increased from the same quarter the previous year. Regardless of the strong results of the gross profit margin, the net profit margin of 1.20% trails the industry average.
  • OMCL has no debt to speak of therefore resulting in a debt-to-equity ratio of zero, which we consider to be a relatively favorable sign. Along with this, the company maintains a quick ratio of 3.87, which clearly demonstrates the ability to cover short-term cash needs.
  • The revenue growth significantly trails the industry average of 47.6%. Since the same quarter one year prior, revenues slightly increased by 5.5%. This growth in revenue does not appear to have trickled down to the company's bottom line, displayed by a decline in earnings per share.

Omnicell, Inc. develops, markets, sells, and supports medication and supply dispensing systems to the healthcare industry primarily in the United States and Canada. The company has a P/E ratio of 116.7, equal to the average computer hardware industry P/E ratio and above the S&P 500 P/E ratio of 17.7. Omnicell has a market cap of $541.2 million and is part of the technology sector and computer hardware industry. Shares are up 15.2% year to date as of the close of trading on Friday.

You can view the full Omnicell Ratings Report or get investment ideas from our investment research center.

null

More from Markets

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

Oil Falls Sharply After Saudi Arabia, Russia Suggest Production Cut Easing

Oil Falls Sharply After Saudi Arabia, Russia Suggest Production Cut Easing

North Korea, Apple, GPDR and Gap - 5 Things You Must Know

North Korea, Apple, GPDR and Gap - 5 Things You Must Know

Netflix Ready to Surpass Disney as America's Most Valuable Media Company

Netflix Ready to Surpass Disney as America's Most Valuable Media Company

Global Stocks Hold Gains as North Korea Response on Talks Soothes Nerves

Global Stocks Hold Gains as North Korea Response on Talks Soothes Nerves